Результаты поиска

[Simultaneous determination of 61 hormones in water by solid phase extraction-ultra performance liquid chromatography-tandem mass spectrometry].

Concerns over the emergence of steroid hormones as pollutants in water have grown. Steroid hormone compounds present challenges in the simul … , n=6) of 1.1%-10.5%. Using this method, we successfully detected 10 hormone components (cortisone, fluticasone propionate, ciclesonide, betamethasone dipropionate, clobetasone butyrate, diflucortolone valerate, halobetasol propionate, isoflupredone, difluprednate, and hydroxyprogesterone caproate) in various surface water and groundwater samples collected fr …

Regulation of YKL-40 expression by corticosteroids: effect on pro-inflammatory macrophages in vitro and its modulation in COPD in vivo.

BACKGROUND: Macrophages constitute a heterogeneous cell population with pro- (MΦ1) and anti-inflammatory (MΦ2) cells. The soluble chitinase-like-protein YKL-40 is expressed in macrophages and various other cell types, and has been linked to a variety of inflammatory diseases, including COPD. Dexamethasone strongly reduces YKL-40 expression in peripheral blood mononuclear cells (PBMC) in vitro. We hypothesized that: a) YKL-40 is differentially expressed by MΦ1 and MΦ2, b) is decreased by corticosteroids and c) that long-term treatment with inhaled corticosteroids (ICS) affects YKL-40 levels in

Maternal asthma medication use and the risk of selected birth defects.

OBJECTIVES: Approximately 4% to 12% of pregnant women have asthma; few studies have examined the effects of maternal asthma medication use on birth defects. We examined whether maternal asthma medication use during early pregnancy increased the risk of selected birth defects. METHODS: National Birth Defects Prevention Study data for 2853 infants with 1 or more selected birth defects (diaphragmatic hernia, esophageal atresia, small intestinal atresia, anorectal atresia, neural tube defects, omphalocele, or limb deficiencies) and 6726 unaffected control infants delivered from October 1997 throu

Ontology-based collection, representation and analysis of drug-associated neuropathy adverse events.

BackgroundNeuropathy often occurs following drug treatment such as chemotherapy. Severe instances of neuropathy can result in cessation of life-saving chemotherapy treatment.ResultsTo support data representation and analysis of drug-associated neuropathy adverse events (AEs), we developed the Ontology of Drug Neuropathy Adverse Events (ODNAE). ODNAE extends the Ontology of Adverse Events (OAE). Our combinatorial approach identified 215 US FDA-licensed small molecule drugs that induce signs and symptoms of various types of neuropathy. ODNAE imports related drugs from the Drug Ontology (DrON) wi

Совпадение в полном тексте источника
… , Fluticasone propionate, antagonists 2: Bicalutamide, Megestrol modulators 3. … , Fluticasone propionate, antagonists | 2: Bicalutamide, Megestrol modulators | 3. …

Errors in Aerosol Inhaler Use and Their Effects on Maternal and Fetal Outcomes among Pregnant Asthmatic Women (Subanalysis from QAKCOP Study).

Data on inhaler technique and its effects on maternal and fetal outcomes during pregnancy are seldom reported. The primary objective of this study was to evaluate inhaler technique and identify errors in inhaler use among pregnant women with asthma. Secondary objectives were to identify factors associated with poor inhaler technique and study the association between inhaler technique and maternal and fetal outcomes. This was a cross-sectional, face-to-face, prospective study of 80 pregnant women with physician-diagnosed asthma. Seventy-three and 41 asthmatic pregnant women reported using press

A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis.

BACKGROUND: Bronchiectasis is a long-term lung condition associated with bronchial dilatation, chronic inflammation and infection. Treatment … gonists) and 22 μg vilanterol (long-acting beta agonists)], triple therapy [dual therapy plus 92 μg fluticasone furoate (inhaled corticosteroid)] or matched placebo dry powder inhalers, randomised in a 2 : 2 : 1 ratio, respectively. OUTCOME MEASURES: Primary: number of participants reported bronchiectasis exacerbations requiring treatment with antibiotics du …

The current epidemiology of cutaneous malignant melanoma.

BACKGROUND: Corticosteroids are considered to be particularly effective in reducing nasal congestion and are therefore recommended as first-line treatment in allergic rhinitis patients with moderate to severe and/or persistent symptoms. OBJECTIVE: We compared the clinical efficacy of fluticasone propionate aqueous nasal spray (FPANS) 200 microg given once daily, administered in mono-therapy or combined therapy with a H1 receptor antagonist (cetirizine, CTZ) or with a leukotriene antagonist (montelukast, MSK), and the combined therapy of CTZ plus MSK in the treatment of patients affected by al…

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.

BACKGROUND: Roflumilast, a once-daily, selective phosphodiesterase-4 inhibitor, reduces the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. The RE(2)SPOND study is examining whether roflumilast, when added to an inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) fixed-dose combination (FDC), further reduces exacerbations. The methodology is described herein. METHODS: In this Phase IV, multicenter, double-blind, placebo-controlled, parallel-group trial, participants were randomized 1:1 (stratified by long-acting m

Clinical impact of airflow obstruction after allogeneic hematopoietic stem cell transplantation.

Criteria for airflow obstruction (AFO) at one year after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in pulmonary function tests (PFTs) are more stringent than the bronchiolitis obliterans syndrome (BOS) criteria of the National Institutes of Health. This single-center, retrospective cohort study evaluated the clinical impact of the AFO criteria at any time after transplantation. In 132 patients who underwent allo-HSCT from 2006 to 2016, the 2-year cumulative incidence of AFO was 35.0%, and the median time to diagnosis of AFO was 101 days after transplantation (range 35-716

Совпадение в полном тексте источника
… The efficacy of inhaled steroids and other treatments for BO has been reported since around 2007 [ 25 , 26 ], and Williams et al. reported that treatment with inhaled fluticasone, azithromycin, and montelukast and a brief steroid pulse stabilized the majority of new-onset BOS patients [ 27 ]. … Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(4):710–6. 10.1016/j.bbmt.2015.10.009. 26475726 10.1016/j.bbmt.2015.10.009 PMC4801753 28. …

Chemokines in COPD: From Implication to Therapeutic Use.

: Chronic Obstructive Pulmonary Disease (COPD) represents the 3rd leading cause of death in the world. The underlying pathophysiological mechanisms have been the focus of extensive research in the past. The lung has a complex architecture, where structural cells interact continuously with immune cells that infiltrate into the pulmonary tissue. Both types of cells express chemokines and chemokine receptors, making them sensitive to modifications of concentration gradients. Cigarette smoke exposure and recurrent exacerbations, directly and indirectly, impact the expression of chemokines and chem

Совпадение в полном тексте источника
… TORCH investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N. Engl. J. Med. 2007 356 775 789 10.1056/NEJMoa063070 17314337 11. Tashkin D.P. Celli B. Senn S. Burkhart D. Kesten S. Menjoge S. Decramer M. … Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD N. Engl. J. Med. 2016 374 2222 2234 10.1056/NEJMoa1516385 27181606 14. Lipson D.A. Barnhart F. Brealey N. Brooks J. Criner G.J. Day N.C. Dransfield M.T. Halpin D.M.G. Han M.K. Jones C.E. …

Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease.

Chronic graft-versus-host disease (cGVHD) represents a common long-term complication after allogeneic hematopoietic stem cell transplantation (HSCT). It imposes a significant morbidity burden and is the leading cause of non-relapse mortality among long-term HSCT survivors. cGVHD can manifest in nearly any organ, severely affecting the quality of life of a transplant survivor. While the mainstay of treatment has remained systemic immunosuppression with glucocorticoids, progress has been made within the last few years with approvals of three oral agents to treat steroid-refractory cGVHD: ibrutin

Совпадение в полном тексте источника
… In addition to systemic immunosuppression, the combination of inhaled fluticasone, azithromycin and montelukast (FAM) is now commonly used in the treatment of BOS due to evidence that it improves symptom burden and quality of life, while leading to reductions in systemic steroid exposure. 101,104 While … Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Williams K. M., Cheng G. …

Combination treatment of dupilumab with bortezomib in a patient with IgG kappa gammopathy of renal significance, uremic pruritus and chronic lichenoid dermatitis.

Chronic pruritus (CP) is one of the most frequent symptoms among dermatological conditions, capable of reducing the quality of life (QoL). CP may be induced by atopic dermatitis or other dermatological and/or non-dermatological conditions. In this article, we report the case of a patient affected by generalized CP, characterised by multiple papulo-nodular and escoriatic lesions, developed after the onset of an immunoglobulin G (IgG) kappa monoclonal gammopathy of renal significance (MGRS), associated with renal insufficiency. Therefore, a combined treatment with dupilumab for CP and bortezomib

Совпадение в полном тексте источника
… The patient’s personal medical history was positive for atopy and asthma (occasionally treated with fluticasone proprionate/formoterol fumarate); accordingly, a cutaneous biopsy was performed. …

Chronic obstructive pulmonary disease with short-acting inhaled pharmacotherapy increases the risk of prostate cancer: A two-stage database approach.

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) are at a higher risk of many types of cancer. However, specific investigation of the risk of prostate cancer and the influence of COPD pharmacotherapy in patients with COPD is lacking. This study investigated the risk and influence of COPD pharmacotherapy on risk of prostate cancer in patients with COPD. METHODS: This retrospective cohort study used data from Taiwan's Longitudinal Health Insurance Database 2005 (LHID2005). The study cohort comprised COPD patients who received treatment between 2004 and 2008, and who were i

Совпадение в полном тексте источника
… HandiHaler (Spiriva, Boehringer Ingelheim); (4) long-acting β-agonists (LABAs): formoterol Turbuhaler (Oxis, AstraZeneca) or salmeterol MDI (Serevent, GlaxoSmithKline); and (5) LABAs plus inhaled corticosteroids (ICSs): formoterol plus budesonide Turbuhaler (Symbicort, AstraZeneca) or salmeterol plus fluticasone … Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. The New England journal of medicine. 2007;356(8):775–89. 10.1056/NEJMoa063070 . 38. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. …

NAPCON 2025 – Best Original Research Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… is limited real-world data on Indian asthma patients treated with inhaled Fluticasone Propionate/Formoterol (FP/FORM). … : The FDC of Fluticasone Furoate and Vilanterol trifenatate (FF/VI) is an ultra-long-acting ICS/LABA indicated for asthma. …

Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with recessive dystrophic epidermolysis bullosa (MissionEB): a randomised, double-blind, placebo controlled, crossover, phase 3 trial with an internal phase 1 dose de-escalation phase.

BACKGROUND: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genetic disorder characterised by extensive mucocutaneous blistering … ive days within 30 days of enrolment into this study, excluding oral viscous budesonide and inhaled fluticasone used as prophylaxis to relieve oesophageal symptoms, an active infection that required treatment with oral or intravenous antibiotics within 7 days of screening, medical history or evidence of active malignancy, the presence of both positive collage …

Localized nasopharyngeal amyloidosis: A case report.

Amyloidosis is a rare condition on its own but finding localized amyloidosis of a site such as the nasopharynx is an extremely rare condition with very few cases described in the literature. The condition occurs due to the accumulation of misfolded proteins in the extracellular space disrupting the cell architecture and causing eventual dysfunction. In this case report we discuss the pathophysiology, symptoms, and imaging findings of a patient initially thought to have giant cell arteritis, but who was found on CT to have a mass later determined to be localized nasopharyngeal amyloidosis. Eval

Совпадение в полном тексте источника
… For 3 weeks, our patient has also experienced intermittent nasal congestion and foul-tasting nasal discharge that was responsive to Fluticasone nasal spray. …

Strongyloides stercoralis hyperinfection after corticosteroid therapy: a report of two cases.

Two cases of Strongyloides stercoralis hyperinfection are described. Both patients were expatriates from the Indian subcontinent, and reported the use of corticosteroids. The first patient presented with severe pulmonary disease that necessitated respiratory support, followed by acute abdomen and intestinal obstruction and he succumbed to these diseases. The second patient also presented with acute pulmonary disease, which responded to antihelmintic treatment and supportive care; however, he died later due to his primary disease. The clinical features of S stercoralis hyperinfection are nonspe

Совпадение в полном тексте источника
… He was maintained on salbutamol inhaler, fluticasone, and salmetrol discus inhaler, theophylline and home oxygen therapy. He denied receiving systemic corticosteroids in the preceding year. He was an ex-smoker and alcohol drinker. …

Recent trends in specialty pharma business model.

The recent rise of specialty pharma is attributed to its flexible, versatile, and open business model while the traditional big pharma is facing a challenging time with patent cliff, generic threat, and low research and development (R&D) productivity. These multinational pharmaceutical companies, facing a difficult time, have been systematically externalizing R&D and some even establish their own corporate venture capital so as to diversify with more shots on goal, with the hope of achieving a higher success rate in their compound pipeline. Biologics and clinical Phase II proof-of-concept (POC

Совпадение в полном тексте источника
… Mylan acquired again in November 2011, the rights from Pfizer to make generic versions of two GlaxoSmithKline respiratory drugs: Advair Diskus (fluticasone propionate) and Seretide Diskus (fluticasone propionate and salmeterol) using Pfizer’s proprietary dry-powder inhaler delivery system [ 15 ]. …

Abstracts for NAPCON 2025

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… combination ( n =402) | Pulmonologist (%) | Physician (%) | Paediatrician (%) | Total (%) Beclomethasone + Levosalbutamol | 12.8 | 15.1 | 17.1 | 14.1 Budesonide + Formoterol | 44.6 | 38.2 | 56.1 | 43.0 Beclomethasone + Formoterol | 12.6 | 15.1 | 12.2 | 13.5 Mometasone + Formoterol | 5.6 | 5.9 | 1.2 | 5.3 Fluticasone …